Polyester-Based Nanoparticles for the Encapsulation of Monoclonal Antibodies

  • Flávia Sousa
  • Pedro Fonte
  • Andreia Cruz
  • Patrick J. Kennedy
  • Inês Mendes Pinto
  • Bruno Sarmento
Protocol
First Online:
Part of the Methods in Molecular Biology book series (MIMB, volume 1674)

Abstract

Aliphatic polyesters have been widely explored for biomedical applications (e.g., drug delivery systems, biomedical devices, and tissue engineering). Recently, polyesters have been used in nanoparticle formulations for the controlled release of monoclonal antibodies (mAbs) for the enhanced efficacy of antibody-based therapy. Polyester-based nanoparticles for mAb delivery provide decreased antibody dosage, increased antibody stability and protection and longer therapeutic action, ultimately translating to an increased therapeutic index. Additionally, nanoencapsulation holds the potential for the selective cellular recognition and internalization of mAbs, in the disease context when intracellular organelles and molecules (e.g., enzymes, transcription factors and oncogenic proteins) are the preferred target. We present here a detailed method to prepare mAb-loaded polyester-based nanoparticles and the various techniques to characterize the resulting nanoparticles and mAb structure. Finally, we highlight different biological approaches to assess the in vitro bioactivity of the antibody upon nanoparticle release.

Key words

Polyester Polymeric nanoparticles Monoclonal antibodies Controlled release Antibody delivery Antibody structure Antibody bioactivity Anti-VEGF Angiogenesis Endothelial cells 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

Flávia Sousa would like to thank to Fundação para a Ciência e a Tecnologia (FCT), Portugal for financial support (Grant SFRH/BD/112201/2015). Patrick J. Kennedy gratefully acknowledges the BiotechHealth Programme (Doctoral Programme in Cellular and Molecular Biotechnology Applied to Health Sciences) and FCT for financial support (SFRH/BD/99036/2013) and beyond. This work was also financed by FEDER—Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020—Operational Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT—Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Inovação in the framework of the projects “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274) and UID/BIM/04293/2013.

References

  1. 1.
    Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12(4):278–287CrossRefPubMedGoogle Scholar
  2. 2.
    Li J, Zhu Z (2010) Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin 31(9):1198–1207CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ecker DM, Jones SD, Levine HL (2015) The therapeutic monoclonal antibody market. mAbs 7(1):9–14CrossRefPubMedGoogle Scholar
  4. 4.
    Chames P, Van Regenmortel M, Weiss E, Baty D (2009) Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157(2):220–233CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Modjtahedi H, Ali S, Essapen S (2012) Therapeutic application of monoclonal antibodies in cancer: advances and challenges. Br Med Bull 104(1):41–59CrossRefPubMedGoogle Scholar
  6. 6.
    Beckman RA, Weiner LM, Davis HM (2007) Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109(2):170–179CrossRefPubMedGoogle Scholar
  7. 7.
    Thurber GM, Schmidt MM, Wittrup KD (2008) Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60(12):1421CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Samaranayake H, Wirth T, Schenkwein D, Raty JK, Yla-Herttuala S (2009) Challenges in monoclonal antibody-based therapies. Ann Med 41(5):322–331CrossRefPubMedGoogle Scholar
  9. 9.
    Arruebo M, Valladares M, González-Fernández Á (2009) Antibody-conjugated nanoparticles for biomedical applications. J Nanomater 2009:24CrossRefGoogle Scholar
  10. 10.
    Ravikumar M (2016) Handbook of polyester drug delivery systems. Pan Stanford, USAGoogle Scholar
  11. 11.
    Marin E, Briceño MI, Caballero-George C (2013) Critical evaluation of biodegradable polymers used in nanodrugs. Int J Nanomedicine 8:3071–3091PubMedPubMedCentralGoogle Scholar
  12. 12.
    Varshochian R, Jeddi-Tehrani M, Mahmoudi AR, Khoshayand MR, Atyabi F, Sabzevari A, Esfahani MR, Dinarvand R (2013) The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments. Eur J Pharm Sci 50(3–4):341–352CrossRefPubMedGoogle Scholar
  13. 13.
    Son S, Lee WR, Joung YK, Kwon MH, Kim YS, Park KD (2009) Optimized stability retention of a monoclonal antibody in the PLGA nanoparticles. Int J Pharm 368(1–2):178–185CrossRefPubMedGoogle Scholar
  14. 14.
    Grainger DW (2004) Controlled-release and local delivery of therapeutic antibodies. Expert Opin Biol Ther 4(7):1029–1044CrossRefPubMedGoogle Scholar
  15. 15.
    Yadav SC, Kumari A, Yadav R (2011) Development of peptide and protein nanotherapeutics by nanoencapsulation and nanobioconjugation. Peptides 32(1):173–187CrossRefPubMedGoogle Scholar
  16. 16.
    Cardoso MM, Peca IN, Roque AC (2012) Antibody-conjugated nanoparticles for therapeutic applications. Curr Med Chem 19(19):3103–3127CrossRefPubMedGoogle Scholar
  17. 17.
    Srinivasan AR, Lakshmikuttyamma A, Shoyele SA (2013) Investigation of the stability and cellular uptake of self-associated monoclonal antibody (MAb) nanoparticles by non-small lung cancer cells. Mol Pharm 10(9):3275–3284CrossRefPubMedGoogle Scholar
  18. 18.
    Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F (2006) Nanoencapsulation: I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2(1):8–21CrossRefGoogle Scholar
  19. 19.
    Li F, Hurley B, Liu Y, Leonard B, Griffith M (2012) Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol J 6:54–58CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gdowski A, Ranjan A, Mukerjee A, Vishwanatha J (2015) Development of biodegradable nanocarriers loaded with a monoclonal antibody. Int J Mol Sci 16(2):3990–3995CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Almeida A, Souto E (2007) Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 59(6):478–490CrossRefPubMedGoogle Scholar
  22. 22.
    Shoyele SA, Slowey A (2006) Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. Int J Pharm 314(1):1–8CrossRefPubMedGoogle Scholar
  23. 23.
    Fonte P, Soares S, Sousa F, Costa A, Seabra V, Reis S, Sarmento B (2014) Stability study perspective of the effect of freeze-drying using cryoprotectants on the structure of insulin loaded into PLGA nanoparticles. Biomacromolecules 15(10):3753–3765CrossRefPubMedGoogle Scholar
  24. 24.
    Hawe A, Kasper JC, Friess W, Jiskoot W (2009) Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress. Eur J Pharm Sci 38(2):79–87CrossRefPubMedGoogle Scholar
  25. 25.
    Sarmento B, Ferreira DC, Jorgensen L, van de Weert M (2007) Probing insulin’s secondary structure after entrapment into alginate/chitosan nanoparticles. Eur J Pharm Biopharm 65(1):10–17CrossRefPubMedGoogle Scholar
  26. 26.
    Greenfield NJ (2006) Using circular dichroism spectra to estimate protein secondary structure. Nat Protoc 1(6):2876–2890CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Chelius D, Ruf P, Plöscher M, Liedtke R, Gansberger E, Hess J, Wasiliu M, Lindhofer H (2010) Structural and functional characterization of the trifunctional antibody catumaxomab. mAbs 2(3):309–319CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Garidel P, Hegyi M, Bassarab S, Weichel M (2008) A rapid, sensitive and economical assessment of monoclonal antibody conformational stability by intrinsic tryptophan fluorescence spectroscopy. Biotechnol J 3(9–10):1201–1211CrossRefPubMedGoogle Scholar
  29. 29.
    Oliveira Silva C, Petersen SB, Pinto Reis C, Rijo P, Molpeceres J, Vorum H, Neves-Petersen MT (2015) Lysozyme photochemistry as a function of temperature. The protective effect of nanoparticles on lysozyme photostability. PLoS One 10(12):e0144454CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8(8):579–591CrossRefPubMedGoogle Scholar
  31. 31.
    Wang Y, Fei D, Vanderlaan M, Song A (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7(4):335–345CrossRefPubMedGoogle Scholar
  32. 32.
    Goel HL, Mercurio AM (2013) VEGF targets the tumour cell. Nat Rev Cancer 13(12):871–882CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Ferrara N, Hillan KJ, Gerber H-P, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391–400CrossRefPubMedGoogle Scholar
  34. 34.
    Carneiro A, Falcao M, Azevedo I, Falcao Reis F, Soares R (2009) Multiple effects of bevacizumab in angiogenesis: implications for its use in age-related macular degeneration. Acta Ophthalmol 87(5):517–523CrossRefPubMedGoogle Scholar
  35. 35.
    Stockert JC, Blázquez-Castro A, Cañete M, Horobin RW, Villanueva Á (2012) MTT assay for cell viability: intracellular localization of the formazan product is in lipid droplets. Acta Histochem 114(8):785–796CrossRefPubMedGoogle Scholar
  36. 36.
    Cell Proliferation ELISA, BrdU (colorimetric). Roche Diagnostics, Mannheim, Germany. http://www.sigmaaldrich.com/catalog/product/roche/11647229001?lang=en&region=NO. Accessed 10 July 2016
  37. 37.
    Shi K, Cui F, Yamamoto H, Kawashima Y (2009) Optimized formulation of high-payload PLGA nanoparticles containing insulin–lauryl sulfate complex. Drug Dev Ind Pharm 35(2):177–184CrossRefPubMedGoogle Scholar
  38. 38.
    Cohen-Sela E, Chorny M, Koroukhov N, Danenberg HD, Golomb G (2009) A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J Control Release 133(2):90–95CrossRefPubMedGoogle Scholar
  39. 39.
    Kelly SM, Price NC (2000) The use of circular dichroism in the investigation of protein structure and function. Curr Protein Pept Sci 1(4):349–384CrossRefPubMedGoogle Scholar
  40. 40.
    Tetin SY, Linthicum DS (1996) Circular dichroism spectroscopy of monoclonal antibodies that bind a superpotent guanidinium sweetener ligand. Biochemistry 35(4):1258–1264CrossRefPubMedGoogle Scholar
  41. 41.
    Joshi V, Shivach T, Yadav N, Rathore AS (2014) Circular dichroism spectroscopy as a tool for monitoring aggregation in monoclonal antibody therapeutics. Anal Chem 86(23):11606–11613CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2018

Authors and Affiliations

  • Flávia Sousa
    • 1
    • 2
    • 3
    • 4
  • Pedro Fonte
    • 5
  • Andreia Cruz
    • 6
  • Patrick J. Kennedy
    • 1
    • 2
    • 3
    • 7
  • Inês Mendes Pinto
    • 6
  • Bruno Sarmento
    • 1
    • 2
    • 3
  1. 1.i3S—Instituto de Investigação e Inovação em SaúdeUniversidade do PortoPortoPortugal
  2. 2.INEB—Instituto Nacional de Engenharia BiomédicaUniversidade do PortoPortoPortugal
  3. 3.ICBAS—Instituto Ciências Biomédicas Abel SalazarUniversidade do PortoPortoPortugal
  4. 4.CESPU—Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da SaúdeGandraPortugal
  5. 5.UCIBIO, REQUIMTE, Department of Chemical Sciences—Applied Chemistry Lab, Faculty of PharmacyUniversity of PortoPortoPortugal
  6. 6.INL, International Iberian Nanotechnology LaboratoryBragaPortugal
  7. 7.IPATIMUP—Instituto de Patologia e Imunologia Molecular da Universidade do PortoPortoPortugal

Personalised recommendations